Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.

Cancer cell - 11 Feb 2013

Shackelford David B, Abt Evan, Gerken Laurie, Vasquez Debbie S, Seki Atsuko, Leblanc Mathias, Wei Liu, Fishbein Michael C, Czernin Johannes, Mischel Paul S, Shaw Reuben J

Abstract excerpt

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Eukaryotic Initiation Factor-2

Share to Hypoglycemic Agents

Share to Mitochondria

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 23352126
DOI: 10.1016/j.ccr.2012.12.008
PMCID: PMC3579627

Genes

STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.PMID 23352126Read ↗

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivatedSemantic proximity Read ↗

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.Semantic proximity Read ↗

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read ↗

Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.Semantic proximity Read ↗

Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressorSemantic proximity Read ↗

Targeting AMPK for Cancer Therapy: Metabolic Reprogramming as a Therapeutic StrategySemantic proximity Read ↗

Insights into targeting LKB1 in tumorigenesisSemantic proximity Read ↗

Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Semantic proximity Read ↗

Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.Semantic proximity Read ↗

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

LKB1-AMPK axis revisited.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.